Genetics of Cystic Fibrosis: Clinical Implications.

[1]  J. Davies,et al.  The future of CFTR modulating therapies for cystic fibrosis , 2015, Current opinion in pulmonary medicine.

[2]  P. Davis.  Another Beginning for Cystic Fibrosis Therapy. , 2015, The New England journal of medicine.

[3]  Xiaohong Huang,et al.  Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. , 2015, The New England journal of medicine.

[4]  A. Nicholson,et al.  Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial , 2015, The Lancet. Respiratory medicine.

[5]  S. McColley,et al.  Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. , 2015, The Lancet. Respiratory medicine.

[6]  E. Alton,et al.  Cystic Fibrosis Gene Therapy in the UK and Elsewhere , 2015, Human gene therapy.

[7]  D. Sheppard,et al.  Chronic ivacaftor treatment: getting F508del-CFTR into more trouble? , 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[8]  Garry R. Cutting,et al.  Cystic fibrosis genetics: from molecular understanding to clinical application , 2014, Nature Reviews Genetics.

[9]  Ying Jiang,et al.  Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). , 2014, The Lancet. Respiratory medicine.

[10]  N. Dokholyan,et al.  Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis , 2014, Science Translational Medicine.

[11]  G. Lukács,et al.  Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression , 2014, Science Translational Medicine.

[12]  S. McColley,et al.  A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. , 2014, The Lancet. Respiratory medicine.

[13]  S. Peltz,et al.  Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. , 2014, The Lancet. Respiratory medicine.

[14]  S. Bicknell,et al.  Effects of ivacaftor in patients with cystic fibrosis who carry the G551D mutation and have severe lung disease. , 2014, Chest.

[15]  Chris Fellner,et al.  CFTR Modulators for the Treatment of Cystic Fibrosis. , 2014, P & T : a peer-reviewed journal for formulary management.

[16]  Hans Clevers,et al.  Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. , 2013, Cell stem cell.

[17]  Marisa Sousa,et al.  Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction. , 2013, Chemistry & biology.

[18]  A. Verkman,et al.  Cystic fibrosis transmembrane regulator correctors and potentiators. , 2013, Cold Spring Harbor perspectives in medicine.

[19]  L. Galietta.  Managing the Underlying Cause of Cystic Fibrosis: A Future Role for Potentiators and Correctors , 2013, Pediatric Drugs.

[20]  J. Mainz,et al.  Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. , 2013, American journal of respiratory and critical care medicine.

[21]  M. Boyle,et al.  A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect. , 2013, The Lancet. Respiratory medicine.

[22]  I. Sermet-Gaudelus.  Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation , 2013, European Respiratory Review.

[23]  D. Gell,et al.  Hemoglobin variants: biochemical properties and clinical correlates. , 2013, Cold Spring Harbor perspectives in medicine.

[24]  M. Wilschanski.  Novel therapeutic approaches for cystic fibrosis. , 2013, Discovery medicine.

[25]  T. Liou,et al.  Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. , 2012, Chest.

[26]  Matthias Griese,et al.  A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. , 2011, The New England journal of medicine.

[27]  P. Negulescu,et al.  Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 , 2011, Proceedings of the National Academy of Sciences.

[28]  J. Clancy,et al.  Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation , 2011, Thorax.

[29]  H. Blau,et al.  Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis , 2011, European Respiratory Journal.

[30]  J. Gustafson,et al.  Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.

[31]  M. Bibikova,et al.  Efficient Gene Targeting in Drosophila With Zinc-Finger Nucleases , 2006, Genetics.

[32]  G. Novelli,et al.  Isolation of CF cell lines corrected at ΔF508-CFTR locus by SFHR-mediated targeting , 2002, Gene Therapy.

[33]  B. Dallapiccola,et al.  Expression of ΔF508 CFTR in normal mouse lung after site-specific modification of CFTR sequences by SFHR , 2001, Gene Therapy.

[34]  K. Kunzelmann,et al.  Targeted replacement of normal and mutant CFTR sequences in human airway epithelial cells using DNA fragments. , 1998, Human molecular genetics.

[35]  S. Magness,et al.  Distinct levels of Sox9 expression mark colon epithelial stem cells that form colonoids in culture. , 2012, American journal of physiology. Gastrointestinal and liver physiology.